The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Iterum Therapeutics plc | SHS | G6333L101 | 4,003 | 1,733,170 | SH | SOLE | 1,733,170 | 0 | 0 | ||
| NextCure Inc | COM | 65343E108 | 6,733 | 838,442 | SH | SOLE | 838,442 | 0 | 0 | ||
| IDEAYA Biosciences Inc | COM | 45166A102 | 55,848 | 2,660,713 | SH | SOLE | 2,660,713 | 0 | 0 | ||